• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Varian

Varian

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. New Cancer Center at Guy's Hospital in London to be Equipped with Varian TrueBeam Treatment Machines

    New Cancer Center at Guy's Hospital in London to be Equipped with Varian TrueBeam Treatment Machines

  2. INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vascular Solutions Inc. (VASC) To Contact The Firm

    INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vascular Solutions Inc. (VASC) To Contact The Firm

  3. Greece’s Darkest Hour Before Its Dawn

    Varian Medical Systems' VAR third-quarter results were in line with our expectations, and we are leaving our fair value estimate unchanged. Overall, revenue increased 7%, and net orders rose 13%, bringing the company's backlog at quarter-end to $1.6 billion. Revenue for the oncology system segment ...

  4. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Solutions, Inc. - VASC

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Solutions, Inc. - VASC

  5. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vascular Solutions Inc.

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vascular Solutions Inc.

  6. AmeriHealth New Jersey Expands Co-Branded Product Offering With Two Additional South Jersey Hospitals

    AmeriHealth New Jersey Expands Co-Branded Product Offering With Two Additional South Jersey Hospitals

  7. AAR CEO Named to the President's Advisory Council on Doing Business in Africa

    AAR CEO Named to the President's Advisory Council on Doing Business in Africa

  8. Research Roundup: Foreign Diversification, Social Comparisons and Consumer Identity

    Varian Medical's VAR third-quarter fiscal 2006 results fall right in line with the seasonal patterns we expected from our current near-term modeling assumptions. The oncology group notched 14% growth, and customer demand continues to reflect a shift toward Varian's next-generation IGRT technology, ...

  9. A Deeper Look at the Applied Materials-Tokyo Electron Merger

    The combination makes plenty of sense and should better position the firm for the future.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.